ALS Ltd Stock
Price
Target price
€11.80
€11.80
-0.840%
-0.1
-0.840%
-
11.12.25 / Frankfurt
WKN: A1J2YC / Name: ALS / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
ALS Ltd Stock
ALS Ltd shows a slight decrease today, losing -€0.100 (-0.840%) compared to yesterday.
Pros and Cons of ALS Ltd in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | -0.840% | -2.479% | -3.279% | 28.261% | 31.844% | 56.291% | 95.041% |
| Seek Ltd | -0.780% | -4.444% | -12.838% | -14.000% | -5.147% | -6.522% | -21.341% |
| Downer EDI Ltd | -0.450% | 1.382% | 2.326% | 30.178% | 41.026% | 88.034% | 36.646% |
| Insperity Inc. | 5.190% | 0.654% | 6.944% | -60.764% | -57.517% | -71.743% | -56.000% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important